Abstract:The essential trace element iron is a key component of hemoglobin, playing a role in erythropoiesis and oxygen transport. In addition, iron plays a key role in several enzymatic and metabolic processes. Iron deficiency causes anemia, whereas iron overload causes organ-related diseases such as heart failure, liver cirrhosis, and diabetes mellitus. Therefore, maintaining iron homeostasis is essential for the survival of nearly all living organisms. Iron overload-related cardiomyopathy is a secondary form of heart disease resulting from iron accumulation in the myocardium and is the leading cause of morbidity in hereditary hemochromatosis, thalassemia major, and other conditions associated with secondary iron overload. A growing body of epidemiological and molecular evidence supports the notion that iron overload is pathogenic and that iron chelation therapy can be clinically beneficial in treating many forms of heart disease. However, the precise mechanisms by which iron overload leads to heart disease are poorly understood. In recent years, significant progress has been made toward understanding the regulatory mechanisms that underlie iron overload in many diseases. In particular, ferroptosis, a newly identified iron-dependent form of cell death, has drawn considerable attention. Ferroptosis has morphological, biochemical, and genetic features that are distinct from other forms of cell death such as apoptosis, necrosis, and autophagy, and mounting evidence suggests that ferroptosis participates in the initiation and progression of many diseases and conditions, including tumorigenesis, ischemia/reperfusion injury, kidney failure, and diseases affecting the nervous system and the hematological system. Although the death of terminally differentiated cardiomyocytes is a crucial pathogenic factor in the development of cardiomyopathy, the underlying mechanism remains unknown. Recently, we reported that inhibiting ferroptosis in mice can protect against both chemotherapy-induced cardiomyopathy and ischemia/reperfusion-induced cardiomyopathy. With respect to the underlying mechanism, we found that excess accumulation of free iron in the mitochondria of cardiomyocytes causes membrane lipid peroxidation, providing new insights into the pathogenic mechanisms that underlie iron overload-associated cardiomyopathy. In this review, we briefly introduce the molecular mechanisms that regulate cardiac iron homeostasis. In addition, we provide an overview of studies regarding the role that iron overload-associated cardiomyopathy and ferroptosis play in the pathogenesis and progression of heart disease. Finally, we discuss the role of targeting ferroptosis as a promising new therapeutic strategy for myocardial chemotherapeutic and ischemia/reperfusion injury.

Expression of ferroportin1, hephaestin and ceruloplasmin in rat heart

[Developmental Expression and Regulation of Divalent Metal Transporter 1 in Rat Heart].

Development and Iron-Dependent Expression of Hephaestin in Different Brain Regions of Rats

Cardiomyocyte-specific overexpression of FPN1 diminishes cardiac hypertrophy induced by chronic intermittent hypoxia

Ferroportin expression in haem oxygenase 1-deficient mice

Ferroportin1 in Hepatocytes and Macrophages Mediates Systemic Iron Homeostasis

Quantitative Study of Iron Metabolism-related Genes Expression in Rat

Minimal Effect of Conditional Ferroportin KO in the Neural Retina Implicates Ferrous Iron in Retinal Iron Overload and Degeneration.

Loss of Cardiac Ferritin H Facilitates Cardiomyopathy via Slc7a11-Mediated Ferroptosis

Post-transcriptional expression of DMT1 in the heart of rat.

[Expression Changes of Hepcidin and Ferroportin 1 in Murine Model of Iron Overload].

The iron exporter ferroportin/Slc40a1 is essential for iron homeostasis

Expression of Ferroportin 1 in Cultured Osteoblast Hfob1.19 under Iron Excess and Deficiency

Iron Loading Inhibits Ferroportin1 Expression in Pc12 Cells

Ferroportin1 in Hepatocytes and Macrophages is Required for the Efficient Mobilization of Body Iron Stores in Mice

Hypoxia-inducible factor-2α mediates the adaptive increase of intestinal ferroportin during iron deficiency in mice

Role of Iron Overload and Ferroptosis in Heart Disease

Expression of Iron-Regulators in the Bone Tissue of Rats with and Without Iron Overload

Hephaestin and ceruloplasmin play distinct but interrelated roles in iron homeostasis in mouse brain.

Mice overexpressing hepcidin suggest ferroportin does not play a major role in Mn homeostasis

The cardinal roles of ferroportin and its partners in controlling cellular iron in and out